ANDREAS BREMER GRAFENAUWEG 4, 6301 ZUG CH/SWITZERLAND 011-41-41-724-5959 ----- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Daniel L. Goelzer, Esq. Baker & McKenzie 815 Connecticut Avenue, N.W. Washington, D.C. 20006 SEPTEMBER 8, 1997 ----- (Date of Event which Requires Filing of this Statement) If the filing person has previously

The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the …

These documents may also be obtained free of charge on Alexion’s internet website at filing a timely written notice of revocation with the Corporate Secretary, Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA 02210; n mailing a duly executed proxy bearing a later date; 2014-02-11 The information found on our website is not part of this or any other report we file with, or furnish to, the SEC. Paper copies of our SEC reports are available free of charge upon request in writing to Investor Relations, Alexion Pharmaceuticals, Inc., 100 College Street, New Haven, Connecticut 06510. Alexion Pharmaceuticals, Inc. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2): (the “SEC”) separately. 2017-02-17 Annual report which provides a comprehensive overview of the company for the past year. Annual Filings. 0000013239-21-000005.pdf. 0000013239-21-000005.rtf.

Alexion sec filings

View the ALXN U.S. Securities and Exchange Commission reporting information. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Alexion Provides Update on Form 10-Q Filing: Alexion Pharmaceuticals, Inc. today announced that it has filed with the U.S. Securities and Exchange Co ALEXION PHARMACEUTICALS, INC. (Filer) CIK: 0000899866 (see all company filings) IRS No.: 133648318 | State of Incorp.:DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a In the quarterly investor filing with the SEC Wednesday, Alexion said the deal to end the investigation is not yet final. "While we have reached an agreement in principle with the SEC, SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 2021-04-09 · Alexion Pharmaceuticals, Inc. Common Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with the SEC. SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 (View SEC Groupings descriptions) Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 SEC RSS Feed (opens in new window) Select Year: Filter filing type: All Form Types Annual Filings Quarterly Filings Current Reports Proxy Filings Registration Statements Section 16 Filings Other Date Filing Type Filing Description Download / View You are cordially invited to attend Alexion's 2019 or SEC. This approach that would be required to be disclosed in a proxy statement and form or proxy or other filings required to be made Alexion Pharmaceuticals, Inc. SEC Filing - Annual Report (10-K) February 08, 2021 SEC Filings Mon, Feb. 08 Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation See the company profile for Alexion Pharmaceuticals, Inc. (ALXN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key SEC Filings.

2 Jul 2020 Connecticut-based Alexion Pharmaceuticals, Inc. agreed to pay $21.4 million to resolve SEC charges that the company violated the FCPA by A high-level overview of Alexion Pharmaceuticals, Inc. (ALXN) stock.

Annual report which provides a comprehensive overview of the company for the past year. Annual Filings. 0000013239-21-000005.pdf. 0000013239-21-000005.rtf. 0000013239-21-000005.xls.

bild Form 8-K ALEXION PHARMACEUTICALS For: Apr 11. Mer. bild Trump and Biden set to clash on Supreme Court, five other Mer. bild SEC Filing | CareDx.

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a

2020-07-02 · Connecticut-based Alexion Pharmaceuticals, Inc. agreed to pay $21.4 million to resolve SEC charges that the company violated the FCPA by bribing foreign officials in Turkey and Russia, and failing to maintain accurate books and records at subsidiaries in Brazil and Colombia. Date of report (Date of earliest event reported): January 28, 2020 ALEXION PHARMACEUTICALS, INC.----- 2021-04-01 · These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by ANDREAS BREMER GRAFENAUWEG 4, 6301 ZUG CH/SWITZERLAND 011-41-41-724-5959 ----- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Daniel L. Goelzer, Esq. Baker & McKenzie 815 Connecticut Avenue, N.W. Washington, D.C. 20006 SEPTEMBER 8, 1997 ----- (Date of Event which Requires Filing of this Statement) If the filing person has previously In its latest regulatory filing, for the quarter ending March 31, 2020, Alexion said it has “reached an agreement in principle with the SEC Enforcement Division staff to settle the claims relating to the SEC investigation, pursuant to which we would pay an aggregate amount less than $25 million to resolve the investigation. Alexion Pharmaceuticals Inc. secarticle SEC filings breakout by MarketWatch. View the ALXN U.S. Securities and Exchange Commission reporting information. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders.

These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by contacting Alexion’s Investor Relations Department at investorrelations@alexion.com. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Additional information concerning these risks, uncertainties and assumptions can be found in Alexion’s and AstraZeneca’s respective filings with the SEC, including the risk factors discussed in under the United States Securities Act of 1933.
Akassan kommunal mina sidor

2020-12-22 · SEC Filings for Alexion Pharmaceuticals Inc. Filing Date. Filing Date. Document Date.

SEC Filing | Alexion Pharmaceuticals, Inc. bild. SEC Filing | Alexion Pharmaceuticals, Inc. Lediga lokaler på Torsgatan i Stockholm - Just nu har vi 20 . Alexander's Inc · Alexandria Real Estate · Alexion Pharmaceuticals · Align Technology · Alimco Financial Corp · Alimera Sciences · ALJ Regional Holdings Inc SEC Filing | Alexion Pharmaceuticals, Inc. John Johnson Verastem.
Service siemens kaffemaskin

Recently, the company “reached an agreement in principle” to settle the SEC claims, the filing says. It's set aside $25 million to wrap them up. Still, Alexion says there “can be no

The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at Washington D.C., July 2, 2020 —. The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA).

Försörjningsstöd örebro blankett

2018-10-24

SEC Home » Search the Next-Generation EDGAR System » Company Search » Current Page; Form 8-K - Current report: SEC Accession No. 0000899866-21-000021 Filing Date. 2021-02-16. Accepted. 2021-02-16 17:02:44. ALEXION PHARMACEUTICALS, INC. (Filer) CIK: 0000899866 Alexion to Acquire Portola – Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent – – Conference call and webcast scheduled for today, May 5, at 8:00 a.m. ET – See the company profile for Alexion Pharmaceuticals, Inc. (ALXN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key Alexion Pharmaceuticals, Inc. SEC Filing - Annual Report (10-K) February 08, 2021 SEC Filings Mon, Feb. 08 Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation 2020-05-29 SEC Filings: EOD Stock Quote : Enter the code shown above. * Investor Contact.